ViewRay® to Host Investor & Analyst Meeting at 2018 ASTRO Annual Meeting in San Antonio
Leading Oncologists to Highlight MRIdian MRI-Guided Adaptive Radiotherapy, Discuss Emergence as a New Potential Standard of Cancer Care
CLEVELAND, Oct. 9, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will hold a meeting for investors and analysts on Monday, October 22, 2018, during the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX.
The meeting will include a brief company update from Scott Drake, President and Chief Executive Officer of ViewRay, followed by presentations from Louis B. Harrison, M.D., FASTRO, Chair and Senior Member, Department of Radiation Oncology at Moffitt Cancer Center and Michael L. Steinberg, M.D., Professor and Chair, Department of Radiation Oncology at the David Geffen School of Medicine at UCLA.
Dr. Harrison will discuss the opportunity for MRI-guided radiotherapy in the treatment of cancer and its potential contribution to personalizing radiation therapy. Dr. Steinberg will share UCLA's experience with MRI-guided radiotherapy using the MRIdian System, including adaptive radiation therapy, emerging functional imaging capabilities of the system, and economic modeling leading to cost effectiveness. Breakfast will be served at the meeting.
Event: |
ViewRay Investor & Analyst Meeting |
Date: |
Monday, October 22, 2018 |
Time: |
7:00 – 9:00 a.m. CT |
Location: |
Omni La Mansión Del Rio, 112 College Street, San Antonio, TX |
As space is limited, please RSVP to Kaitlyn Brosco at [email protected] if you wish to attend the live event.
An audio webcast of the presentation will be available on the investor relations section of ViewRay's website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology helping to transform radiation therapy, resulting in improved treatment outcomes that benefit both patients and health care systems around the world. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov, including the risk factors disclosed in ViewRay's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
SOURCE ViewRay, Inc.
Share this article